Eunju Hurh

Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides

Mark J. Graham, Richard Lee, Teresa Brandt et al. · New England Journal of Medicine · 2017 · 581 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Daniel Gaudet, Ewa Karwatowska‐Prokopczuk, Seth J. Baum et al. · European Heart Journal · 2020 · 277 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

Jordi Rodón, Hussein Tawbi, Anne Thomas et al. · Clinical Cancer Research · 2014 · 231 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Ioanna Gouni‐Berthold, Veronica J. Alexander, Qingqing Yang et al. · The Lancet Diabetes & Endocrinology · 2021 · 226 citations

Medicine, Pharmacology, Pharmacotherapy +2

N-acetyl galactosamine-conjugated antisense drug to <i>APOC3</i> mRNA, triglycerides and atherogenic lipoprotein levels

Veronica Alexander, Shuting Xia, Eunju Hurh et al. · European Heart Journal · 2019 · 224 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17